Elinzanetant for treating vasomotor symptoms caused by adjuvant endocrine treatment to prevent or treat hormone-receptor positive breast cancer [ID6544]
Awaiting development
Reference number: GID-TA11784
Expected publication date: TBC
To appraise the clinical and cost effectiveness of Elinzanetant within its marketing authorisation for treating vasomotor symptoms
ID6544